Conversely, lncARSR was found upregulated in high fatty acid‐treated human HepG2 and NAFLD mouse models, binding YAP1 and further increasing lipid accumulation, a mechanism alleviated when lncARSR was silenced.251. This evidence concerns the gene LNCARSR and metabolic dysfunction-associated steatotic liver disease.